Maike de Wit

机构：Vivantes Klinikum · ORCID：0000-0001-5222-7133

发表论文 214 篇 · 总被引 17181 次 · h-index 45

代表论文

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial (2024 · The Lancet · 被引 136)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial (2024 · Journal of Clinical Oncology · 被引 77)
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network (2024 · Leukemia · 被引 9)
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All‐ Trans Retinoic Acid or Valproic Acid to Decitabine (2024 · European Journal Of Haematology · 被引 7)
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma (2024 · JAMA Oncology · 被引 7)
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial (2024 · Blood Neoplasia · 被引 5)